Clinical Policy: Pediatric Liver Transplant Form
CENTENE
Corporation
Clinical Policy: Pediatric Liver Transplant
Reference Number: CP.MP.120
Date of Last Revision: 05/25
Coding Implications
Revision Log
See Important Reminder at the end of this policy for important regulatory and legal information.
Description
End-stage liver disease presents unique clinical considerations in the pediatric population. Liver transplantation provides a therapeutic option for pediatric patients with end stage disease. This policy establishes the medical necessity requirements for pediatric liver transplants.
Policy/Criteria
Background
Liver transplantation is an effective therapeutic option for an assortment of acute and chronic hepatic disorders that lead to end stage liver disease in the pediatric population. According to the practice guideline of the American Association for the Study of Liver Diseases (AASLD), pediatric liver transplants account for ~7.8% of all liver transplants in the United States.¹ The evaluation of children for liver transplants should include a multidisciplinary team of specialists that achieve psychosocial, neurocognitive, and developmental needs as well as the complex clinical necessities of these patients.
For adult liver transplants (and children ≥ 12 years of age), the Model for End-stage Liver Disease (MELD) formula is commonly utilized to determine assess organ allocation for liver candidates. The Pediatric End-stage Liver Disease (PELD) score was analogously developed for children < 12 years of age and utilizes total serum bilirubin, INR, height, weight, and albumin; however, this scoring system is not ubiquitously utilized.¹
Common indications for pediatric liver transplants are acute liver failure, biliary atresia and other cholestatic diseases, metabolic diseases, immune disorders, and hepatic malignancies. A recent multicenter analysis of the five-year survival of 461 children revealed an 88% survival rate for the first year.⁵ The majority of these children also show strong graft function at five years, but there are multiple chronic post-transplantation complications in extrahepatic organs.⁵
Coding Implications
This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2024, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.
| CPT® Codes | Description |
|---|---|
| 47133 | Donor hepatectomy (including cold preservation), from cadaver donor |
| 47135 | Liver allotransplantation, orthotopic, partial or whole, from cadaver or living donor, any age |
| 47140 | Donor hepatectomy (including cold preservation), from living donor; left lateral segment only (segments II and III) |
| 47141 | Donor hepatectomy (including cold preservation), from living donor; total left lobectomy (segments II, III and IV) |
| 47142 | Donor hepatectomy (including cold preservation), from living donor; total right lobectomy (segments V, VI, VII and VIII) |
| 47143 | Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation, including cholecystectomy, if necessary, and dissection and removal of surrounding soft tissues to prepare the vena cava, portal vein, hepatic artery, and common bile duct for implantation; without trisegment or lobe split |
| 47144 | Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation, including cholecystectomy, if necessary, and dissection and removal of surrounding soft tissues to prepare the vena cava, portal vein, hepatic artery, and common bile duct for implantation; with trisegment split of whole liver graft into 2 partial liver grafts (ie, left lateral segment [segments II and III] and right trisegment [segments I and IV through VIII]) |
| 47145 | Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation, including cholecystectomy, if necessary, and dissection and removal of surrounding soft tissues to prepare the vena cava, portal vein, hepatic artery, and common bile duct for implantation; with lobe split of whole liver graft into 2 partial liver grafts (ie, left lobe [segments II, III, and IV] and right lobe [segments V through VIII]) |
| 47146 | Backbench reconstruction of cadaver or living donor liver graft prior to allotransplantation; venous anastomosis, each |
| 47147 | Backbench reconstruction of cadaver or living donor liver graft prior to allotransplantation; arterial anastomosis, each |
| HCPCS Codes | Description |
|---|---|
| S2152 | Solid organ(s), complete or segmental, single organ or combination of organs; deceased or living donor (s), procurement, transplantation, and related complications; including drugs; supplies; hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services, and the number of days of pre and posttransplant care in the global definition |
| Reviews, Revisions, and Approvals | Review Date | Approval Date |
|---|---|---|
| Policy developed | 02/18 | 04/18 |
| Replaced contraindications regarding psychological condition preventing compliance with medical therapy and “current non-adherence to medical therapy” with “Inability to adhere to the regimen necessary to preserve the transplant, even with caregiver support.” Changed “Review Date” in header to “Date of Last Revision,” and “Date” in the revision log header to “Revision Date” | 08/21 | 08/21 |
| Annual review. References reviewed, updated, and reformatted. | 01/22 | 02/22 |
| Edited contraindications: Replaced “non-hepatic malignancy…” with malignancy with high risk of recurrence or death…; added GFR restriction, added HIV infection with detectable viral load, added stroke, acute coronary syndrome, or MI; added acute renal failure…; added septic shock; added progressive cognitive impairment; replaced “uncontrollable significant dysfunction of another major organ system…” with “Other severe uncontrolled medical condition expected to limit survival after transplant;” slightly reworded substance use contraindication. | 02/22 | 02/22 |
| Annual review. Criteria I.B.1.a.ii. updated to remove “beyond 3 months from procedure.” and added a) Total bilirubin > 6 mg/dL beyond three months from hepatoportoenterostomy b) Total bilirubin remains between 2 to 6 mg/dL. Updated Criteria I.B.1.b. to add “if partial external biliary diversion or ileal exclusion failed or could not be performed.” Removed “acute liver failure associated with encephalopathy” in Criteria I.B.3.a. and added I.B.3.a.i. and ii. Added Criteria I.B.3.c. Budd-Chiari Syndrome. Added, “At the time of diagnosis…” to I.B.4.a.ii. Updated Criteria I.B.4.d. to infantile hemangioma as well as verbiage in I.B.4.d.i. and ii. Removed “that is not responsive to medical therapy” in criteria I.B.5.h. Added, “At the time of diagnosis…” to I.B.5.h.i. through iv. Criteria I.B.5.m.ii. changed from “hyper-ammonia” to “hyperammonemia.” Criteria I.B.7.b. updated to Factor VII and updated to state, “with complications from or failure of medical management.” Removed “that has failed medical therapy” from Criteria I.B.7.c. and added sub criteria i. and ii. Removed “Budd-Chiari Syndrome” from I.B.7.d. and added Hepatopulmonary syndrome (HPS) as I.B.7.d. Added sub criteria i. and ii. Criteria I.C.1. updated from “chronic” to “active” infection. Criteria I.C.3. updated and added note for exclusion of malignancies that transplant could sufficiently address. Criteria I.C.8. updated to remove age requirement. Criteria I.C.18. updated to exclude marijuana use when prescribed by a licensed practitioner and include required commitment to reducing substance use behaviors if urgent transplant timelines are present. Background updated with no impact on criteria. ICD-10 codes removed. References reviewed and updated. Reviewed by internal specialist and external specialist. | 02/23 | 02/23 |
| Annual review. Added HIV points a. - c., under I.C.2. Minor edits to Background with no effect on criteria. References reviewed and updated. | 05/24 | 05/24 |
| Annual review. Removed “at time of diagnosis” from criteria I.B.5.d. and I.B.5.k. Under I.B.7.c. reformatted criteria with no impact to criteria. Under I.C.4. updated glomerular filtration rate from <40 to <30. References reviewed and updated. Reviewed by internal and external specialist. | 05/25 | 05/25 |
Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and any available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.
The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.
This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.
This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.
Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.
This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.
Note: For Medicaid members/enrollees, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.
Note: For Medicare members/enrollees, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at http://www.cms.gov for additional information.
©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.
Walk through this policy with us
Review how this policy can be converted into cited criteria, prior authorization checks, and operational automation.